Sandoz Says An Eli Lilly ADHD Drug Patent Is Invalid

Law360, New York (August 29, 2007, 12:00 AM EDT) -- Sandoz Inc. has launched a preemptive strike against Eli Lilly & Co., asking a New Jersey court to declare that an Eli Lilly patent relating to attention-deficit drug Strattera is invalid and not infringed by a Sandoz-proposed drug.

Sandoz, the U.S.-based generics arm of Novartis AG, filed the declaratory judgment suit against Eli Lilly on Monday, in the U.S. District Court for the District of New Jersey.

At issue is U.S. Patent Number 5,658,590, entitled “Treatment of attention-deficit/hyperactivity disorder,” issued in 1997 and assigned to Eli...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.